Investing in AstraZeneca PLC (AZN)  ➔  Intrinsic value

Prev. close$54.50 
Previous Close$54.50  
Valuation MethodValuePotential 
Chepakovich Model$2.22-96%recalculate
Graham Formula$13.93-74%recalculate

Latest news

11 May

PRESS DIGEST-British Business - May 12 => Reuters 8:54PM

European Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: Reuters => Benzinga 3:39PM

Argentina to get 4 mln AstraZeneca COVID-19 vaccines in May after delays => Reuters 3:23PM

COVID-19 booster shot is likely and ‘it’s okay’: Doctor => Yahoo Finance Video 2:09PM

UPDATE 1-Mexico says U.S. to share AstraZeneca vaccine after testing => Reuters 12:46PM

AstraZeneca CEO Pascal Soriot narrowly wins vote on pay raise => MarketWatch 11:17AM

UPDATE 1-Canada's Alberta province halts AstraZeneca vaccine first shots due to supply issue => Reuters 10:51AM

UPDATE 1-AstraZeneca investors narrowly approve CEO's 2021 pay package => Reuters 9:25AM

AstraZeneca suffers big revolt over Pascal Soriot's pay => The Telegraph 9:13AM

AstraZeneca shareholders narrowly approve CEO pay package => Reuters 9:11AM

Novavax Down Second Straight Day On Concerns About Delays => 9:10AM

UPDATE 3-Brazil suspends use of AstraZeneca vaccine in pregnant women nationally after death => Reuters 8:45AM

Will the Blood Clot Issue Hurt AstraZeneca's Vaccine in the Long Term? => Motley Fool 8:41AM

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers? => Motley Fool 6:20AM

UPDATE 1-Britain seeking constructive engagement on COVID-19 vaccine waivers => Reuters 5:58AM

UPDATE 1-EU says willing to give AstraZeneca more time for vaccine deliveries => Reuters 3:50AM

EU wants AstraZeneca to deliver 120 mln COVID vaccines by end-June => Reuters 3:12AM

10 May

FirstFT: Today’s top stories => Financial Times 8:00PM

AstraZeneca suffers investor rebellion over pay => Financial Times 8:00PM

WHO classifies triple-mutant Covid variant from India as global health risk => Yahoo Finance Video 5:32PM

Was The Smart Money Right About AstraZeneca plc (AZN)? => Insider Monkey 4:55PM

FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic => Benzinga 4:44PM

COVID-19 is not at the point yet where we can have mass gatherings: Doctor => Yahoo Finance Video 1:53PM

UPDATE 1-AstraZeneca reaches vaccine shipping milestone as EU sues again => Reuters 12:12PM

It’s ‘very possible’ we will continue seasonal mask-wearing: UCLA Assistant Professor => Yahoo Finance Video 11:58AM

EU won’t renew AstraZeneca COVID-19 vaccine; Pfizer shot will take precedence => MarketWatch 11:40AM

AstraZeneca finally reaches vaccine shipping milestone to EU that was due in January => Reuters 11:37AM

EU to launch new legal action against AstraZeneca over vaccine deliveries => Reuters 11:11AM

UPDATE 1-One AZ COVID-19 vaccine dose gives 80% lower death risk - English data => Reuters 11:07AM

India’s COVID crisis deepens, as BioNTech says there’s no evidence its vaccine needs adapting to cope with new variants => MarketWatch 10:51AM

AstraZeneca CEO’s pay package contested by investors => MarketWatch 9:02AM

AstraZeneca plan to beef up CEO Soriot's pay packet faces scrutiny at AGM => Reuters 9:00AM

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA => PR Newswire 9:00AM

AstraZeneca plan to beef up CEO Soriot's pay packet faces scrutiny at AGM => Reuters 8:51AM

EU Ditches AstraZeneca Vaccine. It’s Pivoting to Pfizer. => 8:21AM

Norway may drop AstraZeneca, J&J vaccines; EU will not take AstraZeneca one after June => MarketWatch 8:14AM

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer => Benzinga 6:48AM

UPDATE 1-GAVI in talks with China's Sinopharm, other vaccine makers for COVAX doses => Reuters 5:13AM

UPDATE 1-Germany to make J&J's COVID-19 vaccine available to all adults => Reuters 4:48AM

UPDATE 1-Norway should exclude J&J, AstraZeneca from COVID vaccination scheme, says commission => Reuters 4:20AM

Company description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.